ライフサイエンスコーパス: P

1 P. aeruginosa GroEL, a homolog of heat shock protein 60,

2 ncreased pain interference (difference, 2.0; P = .006).

3 -power fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03), whereas there was no significant effect of neg

4 mpared with controls (group effect, F = 8.0; P = .006).

5 lated with shorter PFS (P = .006, P = .0001, P = .002, and P = .0001, respectively).

6 d from age 4.5 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001).

7 antly correlated with shorter PFS (P = .006, P = .0001, P = .002, and P = .0001, respectively).

8 zed mean differences of visual acuity 0.008, P = 0.890; and visual field loss, -0.019, P = 0.819).

9 o, 0.84; 95% confidence interval, 0.70-1.01; P=0.06).

10 1) and 10-2 (beta = 2.57; 95% CI, 1.12-4.01; P = .001) sensitivities, but the 10-2 VF univariable mod

11 8, P = 0.890; and visual field loss, -0.019, P = 0.819).

12 VA (point estimate, 0.03; 95% CI, 0.01-0.05, P = .04), with only DRIL remaining significant in multiv

13 , and high-dose steroids (odds ratio = 5.05; P = 0.01) retained significance in multivariable analysi

14 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001).

15 f the anti-inflammatory mediator arginase-1 (P = 0.005), and a sustained reduction in skin redness (P

16 ), corresponding to a mean decrease of 9.1% (P < 0.0001).

17 hazard ratio [AHR], 2.3; 95% CI, 1.0 to 5.1; P = .04) and > 5 mitoses per 50 high-power fields (AHR,

18 ), but not in the BOS TxP group (53 +/- 10%, P = 0.97).

19 rates of cross-over to resection (5% vs 11%; P< 0.0001) and development of carcinoma (1% vs 3%; P= 0.

20 treated patients, respectively, by month 12 (P = 0.018) and 2.3% (8/353) and 4.5% by month 24 (P = 0.

21 P = 0.002) and longer hospital stays (+12%, P = 0.006).

22 ing spring (129%, P = 0.001) and fall (124%, P = 0.001), respectively, which was consistent across ye

23 an 300 genes in all patients (7.1% vs. 128%; P < 0.001).

24 en by enhanced C uptake during spring (129%, P = 0.001) and fall (124%, P = 0.001), respectively, whi

25 = 1.09, 95% confidence interval: 1.04, 1.14; P for trend < 0.001) were associated with higher risks o

26 dependently predicted MI at months 12 to 15 (P<0.001) and 30 to 33 (P=0.011).

27 higher than in LOD (32%) or controls (15%) (P = .0001).

28 = 1.10, 95% confidence interval: 1.06, 1.15; P for trend < 0.001) and acetaminophen use (for >6 years

29 dent planned myocardial injury cohort (n=15; P<1.33E-04, 1-way repeated measures analysis of variance

30 with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission with ful

31 95% CI 1.04-1.78; adjusted rates 20% vs 16%; P = 0.023), more readmissions (odds ratio 1.57; 95% CI 1

32 o, 3.06; 95% confidence interval, 1.52-6.16; P = 0.002).

33 7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P = .04) but not with heparin plus GPI (0 vs 3 [0.3%]; P

34 ty by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively, over a total of 20 years of foll

35 ion, nor in the colon (FFT: 23% vs LFT: 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) c

36 nts (36.4%), and white male patients (30.2%, P<0.0001).

37 tial shockable rhythms (from 58.9% to 69.2%; P<0.001), there was no difference in unadjusted rate of

38 ction margins (AHR, 0.9; 95% CI, 0.4 to 2.2; P = 0.86).

39 20-35 than in patients with ETDRS level <20 (P = 0.005).

40 d similar rates of cyst growth (19% vs. 20%; P= 0.95) and lower rates of cross-over to resection (5%

41 the disability scale; 95% CI, 0.57 to 1.20; P < .001) than MI (0.20 points on the disability scale;

42 eclined from 61.0% in 2002 to 49.0% in 2014 (P for trend <0.001), while mortality for males declined

43 eclined from 48.6% in 2002 to 32.2% in 2014 (P for trend <0.001).

44 CPO_Abeta17-21 P reduced Abeta-related pathology coupled with cognitive

45 the SLSJ region (relative B-IMD risk: 0.22; P = .04).

46 .018) and 2.3% (8/353) and 4.5% by month 24 (P = 0.145).

47 d all-cause mortality by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively, over a total

48 major adverse cardiovascular events by 25% (P=0.037) during the initial trial phase and the risk of

49 ncomplete hematologic recovery (44% vs. 25%, P<0.001).

50 o, 1.16; 95% confidence interval, 1.08-1.25; P<0.001).

51 justed odds ratio, 4.24; 95% CI, 1.36-13.25; P = .01) were associated with a mole-prone phenotype.

52 PP by warming (29%, P = 0.02) and eCO2 (26%, P = 0.07) was primarily driven by enhanced C uptake duri

53 8%-15.6%; adjusted means $26,604 vs $24,263; P = 0.005), 12.4% longer length of stay (95% CI 2.3%-23.

54 d the risk of coronary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25%

55 ly correlated with baseline hs-TnT (r=-0.27, P=0.001).

56 cular death, and all-cause mortality by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively

57 ce between the groups (FFT: 35% vs LFT: 29%, P = 0.290), neither regarding the overall population, no

58 on of cumulative 6-year GPP by warming (29%, P = 0.02) and eCO2 (26%, P = 0.07) was primarily driven

59 tudinal strain at 1 year (hazard ratio=0.29; P<0.001).

60 ic valves (AVR+ARE: 73.4% versus AVR: 73.3%, P=0.98) and also underwent concomitant cardiac procedure

61 al A, 188 of 254 (74.0%) vs 21 of 254 (8.3%; P < .001), for a difference in proportions of 65.7% (95%

62 001) and development of carcinoma (1% vs 3%; P= 0.008).

63 ut not with heparin plus GPI (0 vs 3 [0.3%]; P = .30).

64 difference, -1.5 days; 95% CI, -3.1 to -0.3; P = .04).

65 5, P<0.001), cardiopulmonary bypass (r=0.30, P=0.007), and aortic cross-clamp times (r=0.32, P=0.004)

66 more confident signal assignment than 1D (31)P NMR, although currently the ubiquitous use of this nov

67 ing calorimetry, and sequential (2)H and (31)P solid-state nuclear magnetic resonance spectroscopy.

68 .007), and aortic cross-clamp times (r=0.32, P=0.004).

69 I at months 12 to 15 (P<0.001) and 30 to 33 (P=0.011).

70 P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) cancer subgroups.

71 the disability scale; 95% CI, 0.06 to 0.35; P = .006).

72 E group (treatment main effect: F1,68 = 5.4, P = .02, d = 0.50, and Delta = 2.4 [95% CI, 0.4-4.5]).

73 ion had decreased fatigue (difference, -1.4; P = .035), whereas patients who underwent autologous rec

74 thatched roof) (aOR = 2.5; 95% CI = 1.0-6.4; P = .048) were associated with positive diagnosis.

75 y correlated with FEV1 %predicted (r = 0.43; P = .008).

76 ocular 24-2 (beta = 1.95; 95% CI, 0.47-3.43; P = .01) and 10-2 (beta = 2.57; 95% CI, 1.12-4.01; P = .

77 LV T1 correlated with RV T1 (r=0.45, P<0.001), cardiopulmonary bypass (r=0.30, P=0.007), and

78 copy number alteration levels (rho = -0.484, P = 2 x 10-10).

79 the GO arm than in the No-GO arm (26% v 49%; P < .001).

80 M (0.50 and 0.48), and DLQI (0.50 and 0.49) (P < .0001 for all).

81 h less >/= grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk in adjusted analyses (odds

82 3%; LDV/SOF, 1.4%; untreated controls, 2.5%; P < .001).

83 adoran origin (aOR = 6.2; 95% CI = 2.8-13.5; P < .001), prior knowledge of CD (aOR = 2.4; 95% CI = 1.

84 o experience complications (odds ratio 1.51, P = 0.002) and longer hospital stays (+12%, P = 0.006).

85 ] in infants = 7,118 and in adults = 11,510, P = 0.070; V1V2 median MFIs of 512 [infants] and 804 [ad

86 Rituximab (odds ratio = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P

87 he NIP group was -0.20 (95% CI: -0.94, 0.54; P = 0.60).

88 .001) and elevated Cr at Day 90 (HR = 2.56, P < .0001) were associated with increased risk of DCGF;

89 correlated with peak colonic gas (r = 0.57; P < .05).

90 s during their office visits (70.2% v 32.6%; P < .001).

91 al B, 192 of 255 (75.3%) vs 25 of 260 (9.6%; P < .001), for a difference in proportions of 65.7% (95%

92 95% CI 1.08-2.29; adjusted rates 10% vs 6%; P = 0.018), and no difference in discharge destination (

93 framing was related to better QOL (B = 2.61; P < .001) and less depression (B = -0.78; P < .001) amon

94 atio for disease progression or death, 0.65; P<0.001).

95 ac procedures (AVR+ARE: 68% versus AVR: 67%, P=0.31).

96 itial long-duration VF was observed (66.67%; P=0.01).

97 2%) and 50 of 57 patients in group B (87.7%; P=0.06).

98 CI, 6.7-15.7, versus 8.7%; 95% CI, 4.2-16.7; P=0.684).

99 adjusted odds ratio, 9.08; 95% CI, 4.0-23.7; P < .001) and increased variability of nevus dermoscopic

100 001), HpAb (0.737, P < 0.001) and OPN(0.713, P < 0.001), respectively.

101 , as well as one-biomarker of PGI/II (0.735, P < 0.001), HpAb (0.737, P < 0.001) and OPN(0.713, P < 0

102 r of PGI/II (0.735, P < 0.001), HpAb (0.737, P < 0.001) and OPN(0.713, P < 0.001), respectively.

103 Early AR (HR = 1.77, P < .001) and elevated Cr at Day 90 (HR = 2.56, P < .000

104 1; P < .001) and less depression (B = -0.78; P < .001) among patients who reported a terminally ill h

105 c factor for recurrence (hazard ratio, 1.78; P=0.005).

106 mensional combination of PGI/II-HpAb (0.786, P < 0.001), PGI/II-OPN (0.787, P < 0.001), and OPN-HpAb

107 -HpAb (0.786, P < 0.001), PGI/II-OPN (0.787, P < 0.001), and OPN-HpAb (0.801, P = 0.006), as well as

108 reduced in the stable LTx group (24 +/- 8%, P = 0.009), but not in the BOS TxP group (53 +/- 10%, P

109 sion after first shock (from 12.3% to 13.8%; P=0.13).

110 iring IBx had far greater impact (HR = 13.8, P < .0001).

111 nowledge of CD (aOR = 2.4; 95% CI = 1.0-5.8; P = .047), and exposure to all 3 at-risk housing types (

112 OPN (0.787, P < 0.001), and OPN-HpAb (0.801, P = 0.006), as well as one-biomarker of PGI/II (0.735, P

113 io 1.55 [95% confidence interval 1.31-1.84], P = 2.67 x 10(-7)).

114 01; NPV, 95.5% versus 86.1%, chi(2) = 18.85, P < 0.01).

115 an with IFN (HR, 0.72; 95% CI, 0.58 to 0.89; P = .003).

116 hours of incubation with nanoceria at pH 9, P. aeruginosa showed drastic morphological changes as a

117 atio, 2.3; 95% confidence interval, 1.1-4.9; P = 0.04).

118 ificity, 94.3% versus 77.3%, chi(2) = 44.90, P < 0.01; NPV, 95.5% versus 86.1%, chi(2) = 18.85, P < 0

119 o, 0.82; 95% confidence interval, 0.75-0.90; P<0.001).

120 djusted effect, 1.47; 95% CI, -0.01 to 2.91; P = .05).

121 .73; 95% confidence interval (CI) 1.03-2.91; P = 0.03].

122 = .51); heterogeneity was high (I(2) = 92%, P < .001).

123 % per year]; HR, 0.65; 95% CI, 0.45 to 0.94; P = .02) by the dietary intervention.

124 s (odds ratio, 0.41; 95% CI, 0.171 to 0.986; P = .046).

125 ndently associated with complete abstinence (P < 0.001 and P = 0.02, respectively) during follow-up.

126 rrelated with pNCC, NCC, and WNK4 abundance (P<0.001 for all).

127 FIs of 15,509 [infants] and 2,290 [adults], P < 0.001; V1V2 median FIs of 23,926 [infants] and 1,538

128 dian MFIs of 512 [infants] and 804 [adults], P = 0.50), whereas infants immunized with the MF59/SF-2

129 FIs of 23,926 [infants] and 1,538 [adults]; P < 0.001).

130 scan quality (P < .001), and increasing age (P < .03).

131 first posttransplant year (78% vs 57%), all P < .001.

132 Daytime MBS were significantly larger (all P < 0.04) by up to 8.5-fold in +DD compared to -DD subje

133 ide concentration (403 versus 320 pg/mL; all P<0.01), more signs of congestion, but no significant di

134 nhibitor of daunorubicin (MRP1), calcein AM (P-gp), and pheophorbide A (BCRP) transport.

135 of alterations in a multivariable analysis (P = 0.019).

136 aining significant in multivariate analysis (P = .006).

137 ated with complete abstinence (P < 0.001 and P = 0.02, respectively) during follow-up.

138 rter PFS (P = .006, P = .0001, P = .002, and P = .0001, respectively).

139 of the ONL (T6 and I6 sectors, P = .007 and P = .009) and photoreceptor layer (N6 sector, P = .038).

140 dy drug compared to placebo ( P < 0.0161 and P < 0.0001, respectively).

141 plaque of symptomatic patients (P=0.021 and P=0.05, respectively), whereas CE grade and the presence

142 densities of M. catarrhalis, S. aureus, and P. jirovecii are unlikely to be of diagnostic value in c

143 controlled at low concentrations (both B and P are less than 1 ppm).

144 Laboratory strains of Escherichia coli and P. aeruginosa were killed by a process of condensing int

145 f the Erythrocyte binding antigen family and P. falciparum reticulocyte binding-like families.

146 ding the N gene (pre-N) or between the N and P genes (N-P) of rHPIV1 bearing a stabilized attenuating

147 rding to the indication for anticoagulation (P for heterogeneity = .49) or the novel oral anticoagula

148 was associated with PLC (P < .001) and arch (P = .006) injuries but not with body (P = .056), longitu

149 rior chamber reaction (P = 0.7) or LPI area (P = 0.9) were noted between the 2 groups.

150 unique feature of respiratory yeasts such as P. pastoris and C. albicans, and it may have novel moonl

151 ; males: 3.4% [IQR, 0.4%-32.9%] of baseline; P < .001).

152 socioeconomic status (SES) at time of birth (P = 0.001), but not parental age nor maternal gestationa

153 In contrast, higher paternal BMI (P < 0.001), maternal prepregnancy BMI (P < 0.001), and l

154 BMI (P < 0.001), maternal prepregnancy BMI (P < 0.001), and lower family socioeconomic status (SES)

155 arch (P = .006) injuries but not with body (P = .056), longitudinal ligaments (P = .412), or disk (P

156 ver, higher on the BSD than on the DSD (both P < 0.05).

157 DSAEK eyes had significantly better BSCVA (P < .001-.037) with lower SE (P < .001-.017) and cylinde

158 affected than to the unaffected of the CDS (P value approximately 0.00001).

159 21 in medium and 1.25 in low volume centers (P < 0.001).

160 f change in 6MWD differed between IG and CG (P = 0.042), with a slight initial increase in the IG dur

161 cy in animal models than expected by chance (P-value <0.006).

162 exchange of charge between the host [Co6Te8(P(n)Pr3)6][C60]3 and the intercalant TCNE.

163 h identification and 4 verification cohorts (P < 2.19 x 10(-7)).

164 p15 (not primed) and Gagp17 (less conserved; P < 0.0001 for both).

165 follow-up, compared with untreated controls (P < .001).

166 marked cytoplasmic to nuclear shift in COPD (P < 0.01).

167 tched nonperforation survivors without a CP (P<0.0001).

168 with lower SE (P < .001-.017) and cylinder (P < .001), independent of surgical indication, compared

169 were dramatically increased out to 28 days (P < 0.05).

170 cases to 9.7 cases per 10,000 patient-days (P = 0.008).

171 3.8 days to 9.4 days per 1,000 patient-days (P = 0.009).

172 r of TTA, 0.06 days; 95% CI, 0.03-0.08 days; P < .001) but was not associated with increased risk of

173 2.3%-23.5%; adjusted means 5.9 vs 5.2 days; P = 0.015), more complications (odds ratio 1.36; 95% CI

174 FAZ area was enlarged at the DCP (P = .001).

175 and no difference in discharge destination (P = 0.11).

176 ignificant predictors of new MA development (P = 0.04, 0.01, 0.04, 0.004, 0.01, respectively).

177 longitudinal ligaments (P = .412), or disk (P = .665) injuries.

178 NET complexes and both microbiota diversity (P = .009) and dominance of Haemophilus species operation

179 Publication bias was not evident (Egger P = .51); heterogeneity was high (I(2) = 92%, P < .001).

180 frequency of substantial hematoma expansion (P = .013).

181 correlated with the predominantly exploited P sources in the seedling experiment: the N2 fixer with

182 ent airway smooth muscle growth by 1.5-fold (P < 0.05), which was dependent on MMP-1 activation.

183 estly by including additional data on foliar P, but doing so may increase the capability of models to

184 Recoveries for P and S were between 94 and 97%, and agreements with the

185 ted with left ventricular ejection fraction (P=0.045) and ventricular-vascular coupling ratio (P=0.04

186 of two nuclear markers (AME and RAG-1) from P. theobaldi, from across the southern QTP.

187 The structure of a QuiC1 enzyme from P. putida reveals that the protein is a fusion of two di

188 PR2] (R: Cy (1), (i)Pr (2)) with discrete Ge-P exo bonds.

189 EG compared to recipients of younger grafts (P < .0001).

190 5% in the conventional fractionation group ( P = .148).

191 tween baseline and 3 months in either group (P >0.1 for all).

192 nificantly higher than those of the H group (P <0.001).

193 ere larger for men than women (heterogeneity P<0.001), but RRs for serious liver complications appear

194 ions appeared higher in women (heterogeneity P<0.001).

195 response at day 7 was significantly higher (P = .001) in the canakinumab-treated group (n = 5 of 7)

196 depending on baseline severity of hypoxemia (P = 0.0003), with harm increasing with PaO2/FiO2 among p

197 ty of models to predict future conditions in P-limited tropical forests, especially when combined wit

198 stionnaire (P < .001), and the SCORAD index (P < .001).

199 high AM colonization grew best on inorganic P.

200 is impaired in aged hearts during ischemia (P < 0.05 vs. young hearts).

201 es: coping behavior with respect to itching (P < .001), quality of life assessed by using the Skindex

202 L) compared with controls (mean, 34.7 ng/L) (P < .001) and had high diagnostic accuracy for patients

203 6 +/- 9.3 U/L vs 7 hours, 24.8 +/- 14.6 U/L, P = 0.298).

204 s highlight the importance of soil- and leaf-P in defining the photosynthetic capacity of TMFs, with

205 d serum Phleum pratense-specific IgE levels (P = .001) compared with those in the control arm.

206 ith body (P = .056), longitudinal ligaments (P = .412), or disk (P = .665) injuries.

207 of the minimum angle of resolution (logMAR), P < 0.001), greater mean BCVA improvement after surgery

208 se postoperative BCVA (0.06 vs. 0.03 logMAR, P = 0.039).

209 ement after surgery (-0.50 vs. -0.32 logMAR, P < 0.001), and slightly worse postoperative BCVA (0.06

210 rved values (47.7 vs 38.6 mL/min per 1.73 m, P < 0.001) and was superior based on observed values (P

211 RIC and 25% (95% CI, 15% to 36%) after MAC ( P = .29).

212 rtality, and HCC in a dose-dependent manner (P for trend <0.0001, <0.0001, and 0.009, respectively).

213 ales (13698 [24.4%]) to receive medications (P < .001), as were non-Hispanic black (105 [14.8%]) and

214 ed to 16h by the conventional reflux method (P<0.05).

215 02+/-2.32 vs. 0.56+/-1.39 ng per milliliter, P=0.02).

216 GA, it was 35 minutes (IQR, 20-74 minutes) (P = .098).

217 ime curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.0

218 ), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in

219 ndently associated with increased mortality (P = 0.003; odds ratio, 1.254; 95% confidence interval, 1

220 Most P. vivax studies must therefore rely on patient samples,

221 llary RNFL was 5.7 mum (95% CI, 4.3-7.1 mum; P < .001) thinner than in children whose mothers had not

222 , the RNFL was 3.5 mum (95% CI, 0.6-6.3 mum; P = .02) thinner than in normal-birth-weight children af

223 gene (pre-N) or between the N and P genes (N-P) of rHPIV1 bearing a stabilized attenuating mutation i

224 However, NAD(P)H FLIM has not been established as a metabolic proxy i

225 nzyme known to catalyse the oxidation of NAD(P)H, is upregulated when p16 is inactivated by looking a

226 Here we discover that NAD(P)H oxidase 4 (NOX4), an enzyme known to catalyse the ox

227 neutrophils compared to healthy neutrophils (P < 0.05).

228 t mutation identified in a patient with NSCL/P.

229 A novel 3D Co-Nx |P-complex-doped carbon grown on flexible exfoliated grap

230 we compared the functional contributions of P. simiae genes to growth in 90 distinct in vitro condit

231 Here, we investigate the function of P. berghei P47 in Anopheles gambiae mosquito infections.

232 After inoculation of P. flocculosa, the tripartite interaction was monitored

233 n agent-based stochastic simulation model of P. falciparum transmission was used to investigate the s

234 so found to significantly reduce the rate of P. mirabilis crystalline biofilm formation on catheters,

235 To understand the adhesive secretions of P. shermani, its components were chemically analysed by

236 mponents regulate precursor mRNA splicing of P-transposable element transcripts in vivo, leading to t

237 d: rs10791286, an intronic variant in OPCML (P=9.89 x 10(-6)), and rs7700147, an intergenic variant (

238 ot phosphatase activity grew best on organic P, whereas the poor N2 fixer and the two non-N2 fixers w

239 ence in procedure duration was seen overall (P = .060).

240 d muscle more effectively compared to oxyMb (P<0.05).

241 the carotid plaque of symptomatic patients (P=0.021 and P=0.05, respectively), whereas CE grade and

242 Cellular and secreted levels of OEA and PEA (P < 0.001-0.001) were increased in response to inflammat

243 hnical and 95% of nontechnical performances (P < 0.001).

244 e significantly correlated with shorter PFS (P = .006, P = .0001, P = .002, and P = .0001, respective

245 r-thiophene (TTT) and alternating phenylene (P) and thiophene (T) units as PTP and TPT.

246 The level of nitrogen (N), phosphorus (P), zinc (Zn), iron (Fe), and copper (Cu) in the fruit p

247 ance of the study drug compared to placebo ( P < 0.0161 and P < 0.0001, respectively).

248 availability, for instance increasing plant P uptake more with a pulsed water supply compared to a r

249 An abnormal PFP was associated with PLC (P < .001) and arch (P = .006) injuries but not with body

250 en stent fracture and the primary end point (P=0.86) or with restenosis (P=0.53).

251 r thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

252 f >90% for detecting carbapenemase-producing P. aeruginosa Class D carbapenemases were the most preva

253 rotein VP3 folds into a globular protruding (P) domain, exposed on the virion surface.

254 the peak power of an ultrashort laser pulse, P, to the critical power of self-focusing, Pcr, playing

255 ickness (P < .001), decreasing scan quality (P < .001), and increasing age (P < .03).

256 essed by using the Skindex-29 questionnaire (P < .001), and the SCORAD index (P < .001).

257 bipolar device at the different flow rates (P > .05 for all outcomes).

258 With the ratio P/Pcr of the peak power of an ultrashort laser pulse, P,

259 45) and ventricular-vascular coupling ratio (P=0.042).

260 in postoperative anterior chamber reaction (P = 0.7) or LPI area (P = 0.9) were noted between the 2

261 , and a sustained reduction in skin redness (P = 0.02), correlating with significant expression of ge

262 ts treated at GR and at MSKCC, respectively (P < 0.01).

263 HU +/- 167 vs 447 HU +/- 166, respectively [P = .241]; 95% confidence interval: -15.1, 60.0), includ

264 th -0.03 +/- 2.8 mg . min(-1), respectively; P = 0.9) or first-phase insulin secretion (-21 +/- 212 c

265 erage of 14+/-9% and 19+/-22%, respectively; P<0.01 for both), which persisted 24 h later.

266 s having high BPE (71% vs 29%, respectively; P < .001).

267 ve anticoagulants (71% vs 42%, respectively; P < .0001).

268 0 +/- 1.5 and 34.3 +/- 1.6 cm, respectively; P = 0.02).

269 compared with 24 +/- 184 mU/L, respectively; P = 0.9).

270 4% at 8 years after rejection, respectively; P<0.001).

271 imary end point (P=0.86) or with restenosis (P=0.53).

272 the WNT16 and RSPO3 loci and fracture risk (P = 0.004 and 4.0 x 10-4, respectively).

273 interest in parts of objects' and rs2898883 (P<6.8 x 10(-9)), which resides within the sixth intron o

274 ecutive function (differences of 0.6-0.7 SD; P=1.2x10(-3)-2.4x10(-4)).

275 better BSCVA (P < .001-.037) with lower SE (P < .001-.017) and cylinder (P < .001), independent of s

276 = .009) and photoreceptor layer (N6 sector, P = .038).

277 the thickness of the ONL (T6 and I6 sectors, P = .007 and P = .009) and photoreceptor layer (N6 secto

278 all RT (central, S3, T3, I3, and N3 sectors, P = .004-.024) and the thickness of the ONL (T6 and I6 s

279 5% CI: 0.50-0.85), though not significantly (P = 0.32).

280 RNA-seq data, but proportions were similar (P = .73) across all genus-level taxonomic categories.

281 m patients with CRSwNP and control subjects (P < .0001).

282 nib and a longer PFS (likelihood ratio test, P = 0.025).

283 ts occurred in 2.0% in fTRA and 2.9% in TFA (P=0.40).

284 ne initiates synthesis on naked RNA and that P serves to enhance the initiation and processivity of t

285 ing a stabilized attenuating mutation in the P/C gene (C(Delta170)).

286 It is defined as the area under the P rofile of S hannon D ifference (PSD).

287 differences with decreasing RNFL thickness (P < .001), decreasing scan quality (P < .001), and incre

288 Using a stringent significance threshold (P<7.1 x 10(-9)), GWAS in the AGP revealed an association

289 ht ventricular end-systolic volume in AF-TR (P<0.001).

290 her serum vitamin D3 levels after treatment (P = 0.007) demonstrated increased skin expression of the

291 jugative DNA transfer in E. coli and trigger P. aeruginosa T6SS killing, but not pilus production.

292 = .49) or the novel oral anticoagulant type (P for heterogeneity = .15).

293 ophilus species operational taxonomic units (P = .01).

294 ) and was superior based on observed values (P = 0.044) but not using last observation-carried forwar

295 (-6)), and rs7700147, an intergenic variant (P=2.93 x 10(-5)).

296 and PISA scores among the study groups with P <0.05.

297 80% higher in older men than in older women (P < 0.001).

298 n ex vivo decreased from age 4.5 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001).

299 erson-years to 99.7 per 100000 person-years (P < .001 for trend).

300 th non-Hispanic white (17119 [23.1%]) youth (P < .001).